Edition:
United States

McKesson Corp (MCK.N)

MCK.N on New York Stock Exchange

152.65USD
23 Feb 2018
Change (% chg)

$2.56 (+1.71%)
Prev Close
$150.09
Open
$150.72
Day's High
$153.05
Day's Low
$150.37
Volume
294,505
Avg. Vol
545,295
52-wk High
$178.86
52-wk Low
$133.90

Chart for

About

McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, government... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $31,823.63
Shares Outstanding(Mil.): 208.47
Dividend: 0.34
Yield (%): 0.89

Financials

  Industry Sector
P/E (TTM): -- 20.66 16.59
EPS (TTM): -- -- --
ROI: -- 11.59 35.07
ROE: -- 13.59 17.79

BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Two-Part Note Offering

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART NOTE OFFERING OF UP TO EUR 750 MILLION - SEC FILING Source text : (http://bit.ly/2H0ogwC) Further company coverage:

Feb 09 2018

BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Notes Due 2028

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL NOTES DUE 2028 OFFERING OF UP TO $600 MILLION - SEC FILING Source text : (http://bit.ly/2G22iIb) Further company coverage:

Feb 09 2018

BRIEF-Mckesson Files Preliminary Prospectus Supplement Related To Potential Offering Of Notes

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL OFFERING OF NOTES DUE 2020 - SEC FILING Source text - http://bit.ly/2FUEDJW Further company coverage:

Feb 07 2018

McKesson says drug prices competitive but not volatile like 2017

U.S. drug wholesaler McKesson Corp said prices of generic drugs were still competitive, but not as volatile as in 2017 when prices fell sharply, which should help the company as it benefits from a major tie-up with Walmart.

Feb 01 2018

UPDATE 3-McKesson says drug prices competitive but not volatile like 2017

* Books tax benefit of $370 mln in 3rd quarter (Adds company commentary on generic drug prices, background, analyst quotes; updates stock prices)

Feb 01 2018

CORRECTED-UPDATE 1-Drug distributor McKesson's quarterly profit beats estimates

Feb 1 McKesson Corp posted a better-than-expected quarterly profit, as the biggest U.S. drug distributor continues to benefit from its tie-up with Walmart .

Feb 01 2018

BRIEF-McKesson Reports Q3 Adjusted Earnings Per Share $3.41

* Q3 GAAP EARNINGS PER SHARE $4.32 FROM CONTINUING OPERATIONS

Feb 01 2018

Drug distributor McKesson posts 42.6 pct rise in quarterly profit

Feb 1 McKesson Corp, the biggest U.S. drug distributor, reported a 42.6 percent rise in quarterly profit on Thursday, partly helped by a $370 million tax benefit related to changes to U.S. tax laws.

Feb 01 2018

Kentucky accuses McKesson of helping fuel opioid epidemic

Kentucky's attorney general on Monday accused drug distributor McKesson Corp of helping fuel the opioid epidemic by failing to halt shipments of suspiciously large or frequent orders by pharmacies of prescription painkillers.

Jan 22 2018

UPDATE 1-Kentucky accuses McKesson of helping fuel opioid epidemic

Jan 22 Kentucky's attorney general on Monday accused drug distributor McKesson Corp of helping fuel the opioid epidemic by failing to halt shipments of suspiciously large or frequent orders by pharmacies of prescription painkillers.

Jan 22 2018

Earnings vs. Estimates